Aberrant aggregation of the misfolded presynaptic protein, α-Synuclein (α-Syn) into Lewy
body (LB) and Lewy neuritis (LN) is a major pathological hallmark of Parkinson's disease …

Parkinson's disease (PD) is the second most common neurodegenerative disorder and the
fastest growing neurologic disease in the world, yet no disease-modifying therapy is …

Amyloid-forming proteins such α-synuclein and tau, which are implicated in Alzheimer's and
Parkinson's disease, can form different fibril structures or strains with distinct toxic properties …

Direct targeting of alpha-synuclein (ASYN) has emerged as a disease-modifying strategy for
Parkinson's disease and other synucleinopathies which is being approached using both …

In Parkinson's disease (PD), and other α-synucleinopathies, α-synuclein (α-Syn) aggregates
form a myriad of conformational and truncational variants. Most antibodies used to detect …

Liquid–liquid phase separation (LLPS) is an emerging phenomenon in cell physiology and
diseases. The weak multivalent interaction prerequisite for LLPS is believed to be facilitated …

Cytoplasmic deposition of aberrantly misfolded α-synuclein (α-Syn) is a common feature of
synucleinopathies, including Parkinson's disease (PD). However, the precise pathogenic …

The aberrant accumulation of α-Synuclein within oligodendrocytes is an enigmatic,
pathological feature specific to Multiple system atrophy (MSA). Since the characterization of …

α-synuclein aggregation is present in Parkinson's disease and other neuropathologies.
Among the assemblies that populate the amyloid formation process, oligomers and short …

Like many neurodegenerative diseases, Parkinson's disease (PD) is characterized by the
formation of proteinaceous aggregates in brain cells. In PD, those proteinaceous aggregates …